Quick Answer
OCULAR THERAPEUTIX, INC reported Research And Development Expense of $197.10 million for the year ending 2025.
- OCULAR THERAPEUTIX, INC showed an increase of +54.4% in Research And Development Expense from 2024 to 2025.
- This data is from OCULAR THERAPEUTIX, INC's annual report (Form 10-K), filed with the SEC on February 5, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $2.40 million | Q3 2013: $2.78 million | Q1 2014: $4.96 million | Q2 2014: $4.29 million | Q3 2014: $4.48 million | Q1 2015: $4.72 million | Q2 2015: $6.74 million | Q3 2015: $8.26 million | Q1 2016: $7.07 million | Q2 2016: $6.98 million | Q3 2016: $5.69 million | Q1 2017: $6.73 million | Q2 2017: $8.12 million | Q3 2017: $8.13 million | Q1 2018: $8.23 million | Q2 2018: $8.75 million | Q3 2018: $9.69 million | Q1 2019: $11.32 million | Q2 2019: $9.41 million | Q3 2019: $10.24 million | Q1 2020: $6.10 million | Q2 2020: $8.02 million | Q3 2020: $6.95 million | Q1 2021: $10.93 million | Q2 2021: $13.86 million | Q3 2021: $12.72 million | Q1 2022: $13.10 million | Q2 2022: $13.10 million | Q3 2022: $13.72 million | Q1 2023: $14.75 million | Q2 2023: $15.09 million | Q3 2023: $15.02 million | Q1 2024: $20.74 million | Q2 2024: $28.86 million | Q3 2024: $37.05 million | Q1 2025: $42.86 million | Q2 2025: $51.08 million | Q3 2025: $52.36 million.
- Over the full 14 years of available data (2012 to 2025), OCULAR THERAPEUTIX, INC's Research And Development Expense has grown by 1,607.9%.
- Historical annual values: Fiscal year 2025: $197.10 million | Fiscal year 2024: $127.64 million | Fiscal year 2023: $61.06 million | Fiscal year 2022: $53.46 million | Fiscal year 2021: $50.08 million | Fiscal year 2020: $28.69 million | Fiscal year 2019: $41.09 million | Fiscal year 2018: $36.92 million | Fiscal year 2017: $30.88 million | Fiscal year 2016: $27.07 million | Fiscal year 2015: $26.61 million | Fiscal year 2014: $18.88 million | Fiscal year 2013: $10.52 million | Fiscal year 2012: $11.54 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: